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ABSTRACT
Cardiosphere-derived cell (CDC) infusion into damaged myocardium has shown some reparative
effect; this could be improved by better selection of patients and cell subtype. CDCs isolated from
patients with ischemic heart disease are able to support vessel formation in vitro but this ability
varies between patients. The primary aim of our study was to investigate whether the vascular
supportive function of CDCs impacts on their therapeutic potential, with the goal of improving
patient stratiﬁcation. A subgroup of patients produced CDCs which did not efﬁciently support ves-
sel formation (poor supporter CDCs), had reduced levels of proliferation and increased senescence,
despite them being isolated in the same manner and having a similar immunophenotype to CDCs
able to support vessel formation. In a rodent model of myocardial infarction, poor supporter CDCs
had a limited reparative effect when compared to CDCs which had efﬁciently supported vessel for-
mation in vitro. This work suggests that not all patients provide cells which are suitable for cell
therapy. Assessing the vascular supportive function of cells could be used to stratify which patients
will truly beneﬁt from cell therapy and those who would be better suited to an allogeneic trans-
plant or regenerative preconditioning of their cells in a precision medicine fashion. This could
reduce costs, culture times and improve clinical outcomes and patient prognosis. Oc STEM CELLS
TRANSLATIONAL MEDICINE 2017;00:000–000
SIGNIFICANCE STATEMENT
This study aimed at developing personalized treatments for heart disease that involved stem/
progenitor cells isolated from the patients’ own heart. During heart surgery, a tiny piece of
heart tissue was taken. Heart cells were gown in the laboratory and screened for signs that
they were healthy and will be beneficial when transplanted back into the patients’ heart. Cells
from some patients grew well; they supported blood vessel formation and improved heart func-
tion while others did not. Our results showed that screening those cells will predict the best
cells to use and the patients that will benefit most from the treatment.
INTRODUCTION
Ischemic heart disease (IHD) is the foremost cause
of mortality worldwide and it is characterized by
inadequate blood supply to the myocardium [1,
2]. Thus, promoting blood vessel regeneration
and/or remodeling, either by administration of
angiogenic factors or cell transplantation, has
emerged as a new therapeutic approach in
patients with IHD. Importantly, an increase in cap-
illary density following bone marrow cell trans-
plantation has been directly correlated with
improvement in cardiac function [3]. However,
risk factors associated with IHD are known to
affect not only the numbers, but the mobilization,
homing, and engraftment of cells, both resident
in the bone marrow and mobilized into the
peripheral circulation [4, 5]. Tissue-speciﬁc pro-
genitor cells may therefore be a better alternative
for cell therapy.
Currently in the cell therapy ﬁeld, there is a
strong interest in selecting the optimal cell type
and patient population to obtain the best thera-
peutic response in vivo. A cardiac cell population
characterized by their ability to form cardio-
spheres (cardiosphere-derived cells or CDCs) has
been successfully isolated from the human heart
by us and others [6–10]. In a head to head
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TISSUE-SPECIFIC PROGENITOR AND STEM CELLS
comparison with bone marrow mesenchymal stromal cells (BM-
MSC), adipose tissue MSC and bone marrow mononuclear cells,
CDC showed a greater therapeutic ability in a rodent model of
myocardial infarction (MI) [11]. Additionally, a recent systematic
review of cardiac progenitor cells (CPCs) in preclinical studies
established CDCs as having the highest level of therapeutic beneﬁt
in small animal models of myocardial ischemia as measured by
improvement in left ventricular ejection fraction (LVEF) [12]. CDCs
have been shown to have a therapeutic beneﬁt in the intracoro-
nary autologous CPC transfer in patients with hypoplastic left
heart syndrome (TICAP) trial, improving right ventricular ejection
fraction (EF) and reducing heart failure status in pediatric patients
[13]. CDCs have also been administered to adult patients who
have suffered a recent MI [14, 15]. While transplantation of these
cells reduced infarct size and increased viable myocardium for
over a year, this was not accompanied by an improvement in ves-
sel density or in left ventricular function [14, 15]. Improving the
cell selection method and the use of potency assays could
improve clinical outcomes.
Blood vessel formation occurs by three main mechanisms
(vasculogenesis, angiogenesis, and arteriogenesis) to which not
only endothelial cells but stromal and other supportive cells are
pivotal [16]. CDCs can support blood vessel formation in vivo in
preclinical models of myocardial ischemia [7, 17, 18], but it is
unknown if CDCs from all IHD patients will have a robust vascular
supportive function. Therefore, the primary aim of our study was
to investigate whether vascular supportive ability of CDCs impacts
on their therapeutic potential and how this may be affected by
associated risk factors or comorbidities.We also aimed at develop-
ing a functional assay that could be used as a potency assay to
select the optimal cells for the right patient cohort, thus providing
a means to personalizing cell therapy as treatment for IHD.
MATERIALS AND METHODS
Patients
Cardiac tissue biopsies were obtained from the right atrial
appendage with informed written consent and ethical approval
granted by the Berkshire Research Ethics Committee (reference
07/H0607/95) and were handled, processed, and stored under a
Human Tissue Authority license (number 11042). Fifty patients
undergoing cardiac surgery at the Cardiothoracic Unit, John Rad-
cliffe Hospital, Oxford, U.K. were recruited with no restriction of
age or comorbidities and providing they were not participating in
other trials. The study was blinded and clinical records were
accessed only to establish the multiple regression model.
Cell Culture
Isolation and culture of CDC was performed according to previ-
ously described protocols [6, 9]. CDCs were cultured on ﬁbronec-
tin coated (0.33 mg/cm2) tissue culture plastic for all assays. Single
donor human BM-MSC (Lonza, Slough, UK, http://www.lonza.
com/) and human umbilical vein endothelial cells (HUVEC, Lonza)
were grown according to the manufacturer’s instructions. All cells
were maintained at 378C, 5% (vol/vol) CO2 with media changes
every 2–3 days.
Flow Cytometry
Expression of cell surface antigens was assessed by ﬂow cytome-
try as described previously [6]. Brieﬂy, cells were incubated with
human FcR block (BD Biosciences, Oxford, UK, http://www.bd.
com/uk/) at 48C for 30 minutes, then incubated at 48C for 30
minutes with the relevant test antibodies: CD31, CD34, CD45,
CD73, CD90 (BD Biosciences), CD44 (Bio-Rad,Watford, UK, http://
www.biorad.com/), CD105 (R&D Systems, Abingdon, UK, http://
www.rnddsystems.com/), CD117, CD133 (Miltenyi Biotec, Bisley,
UK, http://www.miltenyibiotec.com/), or isotype controls. Median
ﬂuorescent intensities and percentage positive cell populations
were measured using a LSRSII ﬂow cytometer and analysis was
conducted using the FACS Diva software (BD Biosciences).
Cell Labeling
A lentiviral vector system expressing green ﬂuorescent protein
(GFP) was used to generate lentiviral particles as previously
described [19]. HUVECs were transduced with lentiviral vector
particles expressing GFP (LV-GFP) at a multiplicity of infection
(MOI) of 3. Typical titers of the LV-GFP stocks were in the range of
6 3 106 to 2 3 107 transducing units per ml. At the MOI used,
over 98% of HUVEC were transduced with no detriment to cell
viability or proliferation.
Tubule Assay
1.5 3 103 GPF-labeled HUVEC, were seeded with 3 3 104 BMSC
or CDCs in endothelial growth medium (EGM)22 (Lonza) in a
coculture assay as previously described [20]. Images were taken
on day 14 using a Nikon TE2000-U microscope (Nikon UK Ltd,
http://www.europe-nikon.com/en_GB/) with the PCI simple soft-
ware (Hamamatsu Photonics, Welwyn Garden City, UK, http://
www.hamamatsu.co.uk/). Image analysis to determine the total
tubule length (TTL) was performed using the AngioSys software
(TCS Cellworks, Buckingham, UK, http://www.cellworks.co.uk/).
The coculture of GFP-HUVEC and BMSC was used as a positive
control, the TTL of test CDCs relative to this control (represented
as 100%) was deﬁned as relative tubule length (RTL). The tubule
formation experiments were performed routinely at CDC passage
2 and repeated as a quality control step at a later passage for
some CDC samples.
For each patient, CDCs sample TTL and RTL were recorded as
mean values, the samples were then ordered by these values and
split into tertiles classiﬁed as: high tubule formation (ﬁrst tertile),
moderate tubule formation (second tertile), and low tubule for-
mation (third tertile).
For subsequent analysis CDCs with a TTL above 4,000 were
referred to as good supporters of angiogenesis and CDCs with a
TTL below 4,000 were referred to as poor supporters of
angiogenesis.
RNA-Sequencing
Total RNA from six CDC samples was isolated using QIAzol and
RNeasy mini kits (QIAgen, Manchester, UK, http://www.qiagen.
com/) according to the manufacturer’s instructions and treated
with DNase I (Promega, Southampton, UK, http://www.promega.
co.uk/) to remove genomic DNA. Library preparation and
sequencing was performed as previously described using Clontech
Smart seq kit [21]. Quality control, trimming, alignment, and dif-
ferential expression analysis using a Bayesian linear mixed effects
model was performed as described elsewhere [21, 22] using Bow-
tie, MMSEQ, and MMDIF [22–24]. Differentially expressed genes
and transcripts were required to have a posterior probability
>0.3. The RNA-sequencing (RNA-seq) data was submitted to the
gene expression omnibus, accession number GSE81827 (http://
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www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?token5mfupcoyovzyxdub&acc5GSE81827).
Gene Enrichment Analysis
Gene sets derived from the RNA-seq data with a posterior proba-
bility >0.3 were analyzed for gene enrichment with DAVID v6.7
[25] [26] and the top 10 signiﬁcantly upregulated (p value .05)
terms in the molecular function (GOTERM_MF_FAT) and biological
processes (GOTERM_BP_FAT) categories selected.
Cytokine Antibody Array
Conditioned media were collected from CDCs (7 good and 5 poor
supporters of angiogenesis) after culturing in EGM-2 media for 48
hours. EGM-2 media incubated for 48 hours in ﬁbronectin (0.33
mg/cm2) coated plates was used as a control. The Proteome Pro-
ﬁler Human XL Cytokine Array Kit (R&D systems) was used accord-
ing to the manufacturer’s instructions. Image Studio version 3.1
analysis software was used to determine signal intensity. Signal
intensity for each protein tested was adjusted for the background
intensity of the ﬁlm and the basal expression level of the condi-
tioned media control.
Migration Assays
Transwells with polycarbonate membranes with 8.0 mm pores
(Appleton Woods) were coated on the top and bottom of the
membrane with ﬁbronectin (0.33 mg/cm2). 4 3 103 CDCs were
added in 0% fetal bovine serum (FBS, Hyclone) Modiﬁed Eagle’s
medium (MEM) to the top of the insert and placed into a well
containing 20% FBS MEM. After 24 hours, the transwell insert was
removed and media removed by aspiration. Nonmigratory cells
were removed from the upper surface by wiping with a cotton
bud. The transwell was rinsed in phosphate buffered saline (PBS)
and cells ﬁxed in 4% (wt/vol) Paraformaldehyde and 4% (wt/vol)
Sucrose in PBS. The membrane was rinsed with PBS, cut out from
the transwell and mounted upside down onto a slide using Vecta-
shield mounting media with 40, 6- diamino-2-phenylindole (DAPI)
(Vectorlabs, Peterborough, UK, http://www.vectorlabs.com/).
Images were captured at 3100 magniﬁcation using an E600
microscope (Nikon), DAPI positive cells were counted using ImageJ
software and the average number of cells per ﬁeld of view was
calculated for each sample.
Immunocytochemistry
CDCs were ﬁxed with 4% (wt/vol) Paraformaldehyde, 4% (wt/vol)
Sucrose in PBS on culture slides (BD Biosciences). For immunocy-
tochemistry - slides were incubated in target retrieval solution
(Agilent Technologies, Stockport, UK, http://www.agilent.com/) at
958C for 30 minutes, rinsed in PBS and permeabilized with 0.1%
(vol/vol) Triton X-100, 3% (vol/vol) FBS, before incubation with
Alexa Fluor 647 mouse anti-human Ki-67 (B56) or Alexa Fluor 647
mouse IgG1 j isotype control (MOPC-21) antibodies (BD Bioscien-
ces) at 48C, overnight. For proliferation, the Click-iT Alexa Fluor
A488 Imaging kit (Thermoﬁsher, Waltham, MA, USA, http://www.
thermoﬁsher.com/) was used according to the manufacturer’s
instructions. Slides were washed in PBS then mounted in Vecta-
shield mounting media with DAPI (Vectorlabs). Images were cap-
tured at 3200 (proliferation) or 3400 (Ki67) magniﬁcation using
an E600 microscope (Nikon), stained cells were counted using
ImageJ software.
Western Blotting
Protein lysates were prepared by re-suspending 1 3 107 cell per
milliliter of Radio-Immunoprecipitation Assay (RIPA) buffer;
50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% (vol/vol) Triton X-100,
0.5% (wt/vol) sodium decoxycholate, 0.1% (wt/vol) sodium
dodecyl sulfate with fresh protease/phosphatase inhibitors (Ther-
moﬁsher). Samples were incubated on ice for 30 minutes before
clearing the lysate by centrifugation at 12,000 rpm at 48C for 30
minutes. Protein concentration was determined using the DC Pro-
tein Assay (Bio-Rad). Twenty-ﬁve microgram of each protein lysate
was treated with b-mercaptoethanol and separated by electro-
phoresis on 4%–12% NuPAGE Bis-Tris gels (Thermoﬁsher) with
rainbow molecular weight marker (GE Healthcare, Amersham, UK,
http://www.ghealthcare.co.uk/) under reducing conditions. Pro-
teins were transferred to nitrocellulose membranes using an iBlot
(Thermoﬁsher) before blocking with Odyssey Blocking Buffer (LI-
COR, Cambridge, UK, http://www.licor.com/). The membranes
were incubated with rabbit anti-caspase 3 (8G10), rabbit anti-
PARP, rabbit anti-p21 (12D1), rabbit anti-Phospho-RB (D20B12)
mouse anti-RB (4H1) (Cell Signaling Technologies, Leiden, Belgium,
http://www.cellsignal.com/) anti-p53 (FL-393, Insight Biotechnolo-
gies, Wembley, UK, http://www.insightbio.com/) or rabbit anti-
p16-INK4A (Protein tech, Manchester, UK, http://www.protein-
technologies.com/) antibodies. Mouse anti-a-tubulin or mouse
anti-GAPDH antibodies (Sigma, Gillingham, UK, http://www.sig-
maaldrich.com/) were used as loading controls. The appropriate
conjugated secondary antibodies were used for detection before
visualizing using the Odyssey CLx system (LI-COR). Signal intensity
above background was measured using the Odyssey CLx system,
protein levels were standardized to loading controls using Micro-
soft Excel.
Apoptosis
To induce apoptosis CDCs were treated with 400 mg/ml hygromy-
cin (Sigma) for 48 hours, control cells were treated with the same
volume of dimethyl sulfoxide (DMSO). Detached and adherent
cells were lysed in RIPA buffer and prepared for Western blotting
as described previously.
Senescence
CDCs were grown for 72 hours to be approximately 50% conﬂu-
ent; cells were ﬁxed and stained using the Senescence b-
Galactosidase Staining Kit (Thermoﬁsher) according to the manu-
facturer’s instructions. The protocol was amended to reduce the
cell staining time from 12 hours to 8 hours to minimize the num-
ber of false positive cells. Images were captured at 3100 using a
TE2000-U microscope (Nikon) and cells were counted using
ImageJ software.
Animals and Cell Transplantation Procedures
All animal experiments were conducted following ethical approval
by the Centro de Investigacion Prıncipe Felipe Research Commit-
tee, Valencia, Spain. Care of animals was in accordance with insti-
tutional guidelines. The ischemic disease model was established
as described previously [27–29]. Ligation of the left anterior
descending (LAD) coronary artery was performed on six- to eight-
week-old athymic nude rats (HIH-Foxn1 rnu, Charles River Labora-
tories, Inc., Lyon, France, http://www.criver.com/) under appropri-
ate anesthesia and analgesia. Following LAD ligation, animals
were divided into three groups to receive: CDC from good
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Figure 1. Cardiosphere-derived cells (CDCs) vary in their supportive ability. (A): The immunophenotype of human CDCs extracted from
patients with ischemic heart disease (IHD) was analyzed by ﬂow cytometry. The total tubule length (TTL) of GFP-labeled human umbilical vein
endothelial cells (HUVECs) was measured after 14 days of coculture with CDCs samples from a total of 43 IHD patients. TTL compared with
control supportive cells BMSC was recorded as relative tubule length (RTL). CDC samples patients were subgrouped into three tertiles based
on their TTL and RTL, the ﬁrst tertile was deﬁned as high tubule formation (n5 14), the second as moderate tubule formation (n5 14), and
the third as low tubule formation (n5 15) (B–D). (B): Representative images of HUVEC tubule formation after 14 days of coculture with CDCs
with high, medium and low tubule formation. Scale bars are equal to 500 mm. Quantiﬁcation of TTL (C) and RTL (D) for the CDC tertiles with
the ranges shown below each graph. Data is presented as mean and standard error of the mean. ***, p value .001.
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supporters (8 animals), CDC from poor supporters (9 animals), or
saline solution (8 animals). Each animal receiving a cell transplant
was injected with CDC from one donor; several donors were used
for the experiments. The intramyocardial transplantation was per-
formed seven days after the LAD ligation in rats that had sub-
acute MI. Animals were infused with 20 ml saline or 1 3 106 cells
per animal and ﬂuorescent microspheres (FluorSpheres; 1 mm red
ﬂuorescent (580/605) polystyrene microspheres, Thermoﬁsher)
diluted 1:40 to visualize the site of injection after tissue process-
ing. For this purpose, three injections were performed at three dif-
ferent points around the infarct zone with a Hamilton syringe
(Teknokroma, Barcelona, Spain, http://www.teknokroma.es/en).
Functional assessment was performed at baseline, 15 days
and 30 days following cell or saline injections by echocardiography
as described elsewhere [27–29]. Brieﬂy, rats were anesthetized
and transthoracic echocardiography was performed in a blinded
manner using a General Electric system (Vivid 7; GE Healthcare)
equipped with a 10-MHz linear-array transducer. Left ventricular
(LV) end-systolic and end-diastolic parameters including diame-
ters, areas, anterior wall and septum thickness were measured on
two-dimensional and M-Mode echocardiograms at the level of
the papillary muscles in the parasternal short axis view, and were
used to derive cardiac function values according to the formulas
in the Supporting Information methods.
Thirty days post-transplantation the rats were sacriﬁced, the
hearts excised and prepared for immunohistochemistry. Vessel
density was determined by immunohistochemistry using a rabbit
anti-caveolin-1 antibody (Thermoﬁsher) and an Alexa Fluor 488
conjugated secondary antibody. Masson’s trichrome staining was
used to assess the remodeling in the left ventricles, as previously
described [27].
Statistical Analysis
Differences between three groups (tertiles of TTL and RTL, animal
experiments) were estimated using one-way ANOVA test and post
hoc two-tailed Student’s t test. For experiments comparing CDCs
with and without hygromycin treatment, one-tailed Student’s t
test was used. For all other statistical analyses two-tailed Student’s
t test was used. p values .05 were considered statistically
signiﬁcant.
A multiple regression model was ﬁtted (using R2.15.1 soft-
ware package) following a Box-Cox transformation to achieve
normality of TTL as the k dependent variable. Age, sex, New
York heart association (NYHA) heart function class, type of dis-
ease (including exact diseased coronary arteries), comorbidity
of hypertension, diabetes, and hypercholesterolemia were
used as independent variables. The adjusted coefﬁcient of
determination (R-squared) was calculated and the analysis was
validated by standard diagnostics of the model’s residuals. Clin-
ical data was from 35 patients. Graphs were produced using
GraphPad Prism version 6.0 software (GraphPad, La Jolla, Ca,
USA, http://www.graphpad.com/).
RESULTS
CDC Vary in Their Ability to Support Endothelial Tubule
Formation
CDCs were isolated from patients with IHD undergoing elective
CABG (Supporting Information Table 1). CDCs expressed high lev-
els of mesenchymal markers (CD105, CD44, and CD73), were
positive for CD90 and negative for endothelial (CD31), hematopoi-
etic (CD34, CD45, and CD133) and stem cell (CD117/c-kit) markers
in agreement with previous results [6–10, 30] (Fig. 1A, Supporting
Information Fig. 1).
Although CDCs can support vessel formation in vivo [7, 17,
18], no previous study has investigated variations in CDCs vascular
supportive function among IHD patient samples as a measure of
potency. In order to test this in vitro CDCs were cocultured with
GFP-labeled HUVECs. The ability of CDCs to support HUVEC tubule
formation visibly varied across the patient sample population (Fig.
1B). TTL and RTL were quantiﬁed for 43 CDC IHD patient samples,
the cohort was then stratiﬁed and grouped into tertiles with clas-
siﬁcations of high, moderate and low tubule formation (Fig. 1C,
1D). TTL and RTL were signiﬁcantly different between all three
groups of tubule formation ability (Fig. 1C, 1D, all comparisons p
value .001). Despite their varying vascular supportive ability, no
signiﬁcant difference in key cell surface markers (CD31, CD34,
CD45, CD90, CD105, CD117, and CD133) was observed between
CDCs with high, moderate or low tubule formation (Supporting
Information Table 2).
Cardiovascular Risk Factors Can Partially Predict CDC
Vascular Supportive Potential
To determine whether the vascular supportive ability of CDCs
could be predicted by disease state or associated risk factors a
multiple regression model was established. In this model, TTL was
used as a dependent variable and demographic and clinical char-
acteristics were included as independent variables (Table 1). The
parameters NYHA class, aortic stenosis, diseased right coronary
artery and history of cigarette smoking were found to be signiﬁ-
cant positive independent predictors of CDCs vascular supportive
Table 1. Independent predictors of the pro-angiogenic potential of
CDCs
Coefﬁcients Estimate SE t value p value
(Intercept) 9.218 6.8 1.356 .1874
Age 20.101 0.083 21.219 .2344
NYHA class 2.636 1.105 2.385 .0250 *
Type of disease AS 7.519 3.581 2.099 .0461 *
CAD 6.703 3.631 1.846 .0768
Others (VR) as control
Diseased RCA 6.558 2.507 2.616 .0149 *
Family history 1.866 1.244 1.5 .1462
Smoking history 5.289 1.974 2.68 .0129 *
Diabetes mellitus 23.364 2.295 21.466 .1552
Hypertension 27.327 2.148 23.411 .0022 **
Residuals
Min 1Q Median 3Q Max
28.2 23.3 0.3 2.7 7.9
Residual standard error: 4.8 on 25 degrees of freedom
Multiple R2: 0.64, Adjusted R2: 0.51
F-statistic: 5.0 on 9 and 25 DF, p value:< .001
A multiple regression model was used to assess whether there was
any independent variable among the correspondent cardiovascular risk
factors to predict pro-angiogenic ability of CDCs. The total tubule
length was used as the dependent variable in the model, clinical char-
acteristics we used as independent variables. Several clinical character-
istics were found to be indicative of CDC supportive ability.
Abbreviations: AS, aortic stenosis; CAD, coronary artery disease; CDC,
cardiosphere-derived cell; NYHA, New York heart association; RCA,
right coronary artery; SE, standard error; VR, valve replacement.
*, p value .05; **, p value .01.
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Figure 2. Good and poor supporter CDCs may differ in their structural organization and cytokine release proﬁle. Genes and transcripts high-
lighted by RNA-sequencing (RNA-seq) as having a differential expression with a posterior probability cut-off of > .3 were analyzed by the
online tool DAVID. The top 10 signiﬁcantly upregulated (p value .05) biological processes (A, B) and molecular functions (C, D) categories
are shown. Full RNA-seq data can be accessed at gene expression omnibus; accession number GSE81827 (http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?token5mfupcoyovzyxdub&acc5GSE81827). Abbreviations: CDCs, cardiosphere-derived cells; ECM, extracellular matrix; GO,
gene ontology; PDGF, platelet derived growth factor.
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Figure 3. Poor supporter cardiosphere-derived cells (CDCs) have an enhanced inﬂammatory proﬁle. The expression of 102 cytokines was
determined by a human cytokine antibody array, 11 cytokines detected by the array had a differential expression between good and poor
supporters in the RNA-sequencing (RNA-seq) array (posterior probability >.3) Gene / transcript levels (A) and protein levels (B) of the 11
overlapping cytokines are shown for good and poor supporter CDCs. (C): Six additional cytokines were signiﬁcantly different between good
and poor supporter CDCs as detected by the cytokine array. For ﬁgure A gene levels are shown for all cytokines except IL-32 where transcript
data is shown. Data is presented as mean and standard error of the mean. 1,posterior probability .3; 11, posterior probability .5; *, p
value .05; **, p value .01; ***, p value .001. Full RNA-seq data for (A) can be accessed at gene expression omnibus; accession number
GSE81827 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token5mfupcoyovzyxdub&acc5GSE81827). Abbreviations: PDGF-AB/BB, plate-
let derived growth factor AB/BB; uPAR, urokinase receptor.
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potential. In contrast, hypertension was a signiﬁcant negative pre-
dictor of the ability of CDCs to form tubules (Table 1). The ﬁnal
model accounted for over 51% of the variability in the data
(R25 0.51).
Differential Gene and Cytokine Expression in CDCs
To simplify subsequent analysis, CDCs with a TTL above 4,000
were referred to as good supporters of angiogenesis (good sup-
porters) and CDCs with a TTL below 4,000 were referred to as
poor supporters of angiogenesis (poor supporters).
Differential gene expression between good and poor sup-
porter CDCs was assessed by RNA-seq. Using a posterior probabil-
ity of >.3, we identiﬁed 54 genes and 88 transcripts upregulated
in good supporters compared to 58 genes and 76 transcripts
upregulated in poor supporter CDCs. Biological processes enriched
in good supporters related to nutrient response and extracellular
components (Fig. 2A, Supporting Information Table 3), while in
poor supporters, they related to the immune response, cell prolif-
eration, cell division and migration (Fig. 2B, Supporting Informa-
tion Table 3). Enriched molecular functions in good supporters
related to extracellular signaling (Fig. 2C, Supporting Information
Table 4), while in poor supporters they related to inﬂammatory
signaling (Fig. 2D, Supporting Information Table 4). The categories
highlighted by the gene ontology (GO) analysis suggested that
good and poor supporter CDCs will differ in their structural organi-
zation of the extracellular matrix (ECM) and cytokine release
proﬁle.
To validate the latter, cytokine secretion by good and poor
supporter CDCs was assessed using an antibody array platform
(Supporting Information Fig. 2). Differences between good and
poor supporters were observed for 11 cytokines that had shown
differential gene expression by RNA-seq (Fig. 3A, 3B). The gene
and protein data from the RNA-seq and cytokine arrays for the 11
cytokines were compared (Fig. 3A, 3B), the majority of the targets
had the same trend and two were signiﬁcantly higher in poor sup-
porters at the gene and protein level (CCL20/Mip-3a and CSF2/
GM-CSF). The cytokine arrays highlighted six additional cytokines
which were signiﬁcantly different between good and poor sup-
porter CDCs (Fig. 3B, 3C). Mip-3a, GM-CSF, Aggrecan, Interleukin
(IL)-19, IL-22, IL-23, and platelet derived growth factor AB/BB
were signiﬁcantly upregulated in poor supporters, while urokinase
receptor was signiﬁcantly upregulated in good supporters (Fig.
3C). Overall, these data suggest that the poor supporters secrete
an increased amount of inﬂammatory cytokines.
Good and Poor Supporter CDCs Differ in Their
Proliferation and Cell Cycle Progression but not in
Migratory Ability
“Locomotory behavior,” “Taxis,” “Chemotaxis,” “Cell division,” and
“Cell proliferation” were enriched biological process in poor sup-
porters (Fig. 2B). However, there was no difference in migratory
ability of the CDCs tested by a Boyden chamber migration assay
(Fig. 4A). Three different assays were used to assess cell prolifera-
tion and cell cycle progression; 5-ethynyl-20-deoxyuridine (EdU)
incorporation, Ki67 expression and phosphorylation state of the
retinoblastoma (Rb) protein, a crucial regulator of the cell cycle.
EdU staining determined that good supporter CDCs had approxi-
mately three times more cells actively proliferating compared to
poor supporter CDCs (Fig. 4B, p value5 .014). This was conﬁrmed
by expression of Ki-67 being detected in 50.61% of good supporter
CDCs and 16% of poor supporter CDCs, indicating that cell cycle
Figure 4. Poor supporter cardiosphere-derived cells (CDCs) have
reduced proliferation and cell cycle progression but do not differ in
migratory ability compared to good supporter CDCs. (A): Migratory
ability of CDCs as shown by the mean number of CDCs which had
migrated through a transwell with 8 mm pores toward a serum gra-
dient after 24 hours of culture, with representative images (3100).
(B): Quantiﬁcation of the percentage of EdU positive CDCs with rep-
resentative images (3200) as measured by a Click-iT proliferation
assay. (C): Quantiﬁcation of Ki67 positive CDCs with representative
images (3400). (D): Quantiﬁcation of the phosphorylated and non-
phosphorylated form of Rb in CDCs with good and poor supportive
potential, with representative images. Scale bars are equal to 100
mm. Data is presented as mean and standard error of the mean. *, p
value .05. Abbreviations: DAPI, 40, 6- diamino-2-phenylindole; NS,
non-signiﬁcant; EdU, 5-ethynyl-20-deoxyuridine; Rb, retinoblastoma.
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progression was signiﬁcantly lower in poor supporter CDCs (Fig.
4C, p value5 .018). Finally, in agreement good supporter CDCs
had a signiﬁcantly higher level of phosphorylated Rb compared to
poor supporters (Fig. 4D, p value5 .031), indicating that cell cycle
progression is reduced in poor supporter CDCs. Together, these
ﬁndings show that the ability for CDCs to progress through the
cell cycle and proliferate is signiﬁcantly diminished in poor sup-
porter CDCs.
Poor Vascular Supportive Function Is Associated With
Resistance to Apoptosis and Senescence
Due to the reduced proliferative capacity of poor supporter CDCs,
we hypothesized that these cells may be undergoing apoptosis.
Cleaved caspase 3 and cleaved poly(ADP-ribose) polymerase
(PARP) are well established markers of early and late apoptosis,
respectively [31, 32]. There were no signiﬁcant differences
between good and poor supporter CDCs in the expression levels
of caspase 3 (full length or cleaved) or full length PARP at basal lev-
els (DMSO treated, Fig. 5A–5F). However, at basal levels cleaved
PARP was ﬁve times higher in poor supporter CDCs than in good
supporter CDCs (Fig. 5F), this was found to be due to 2 of the 4
poor supporters having relatively high levels of cleaved PARP (Fig.
5A, lane 5). This ﬁnding indicated that there may be a higher level
of late apoptosis in some poor supporter CDCs.
Hygromycin treatment induces both early and late apopto-
sis in mammalian cells by blocking the elongation step of trans-
lation [33]. Hygromycin stimulates the cleavage of both
caspase 3 and PARP, this process was seen in the CDCs tested
but the strength of the response varied between good and
poor supporters. The expression levels of caspase 3 and PARP
were compared in DMSO and hygromycin treated CDCs.
Despite a general trend of decreased full length and increased
cleaved fragments of Caspase 3 and PARP, the only signiﬁcant
change was in the downregulation of full length caspase 3 in
good supporter CDCs (Fig. 5B, p value5 .045). In contrast, the
levels of full length caspase 3 in poor supporters were
unchanged after hygromycin treatment (Fig. 5B). Good sup-
porters produced a large increase of the cleaved caspase 3 frag-
ments in response to hygromycin (Fig. 5C, 5D), poor supporters
also responded to hygromycin but the effect was approximately
four times lower than in good supporter CDCs (Fig. 5C, 5D).
Similarly, good supporters induced a large increase in the
cleaved fragment of PARP in response to hygromycin (15-fold
increase), whereas poor supporters were less efﬁcient and only
increase the expression of cleaved PARP by approximately two-
fold after hygromycin treatment (Fig. 5F). Therefore, poor sup-
porter CDCs had a reduced response to pro-apoptotic stimuli
compared to good supporter CDCs, suggesting a resistance to
apoptosis.
Taken together, the enhanced inﬂammatory cytokine proﬁle,
reduced proliferative rates and resistance to apoptotic insult are
hallmarks of cellular senescence [34, 35].When CDCs were stained
Figure 5.
Figure 5. Poor supporters are resistant to apoptosis and have
increased levels of senescence. Early and late apoptosis were meas-
ured in good and poor supporter cardiosphere-derived cells (CDCs)
by analysis of total and cleaved caspase 3 and PARP protein levels.
Apoptosis was induced by hygromycin treatment and compared to
control DMSO treated CDCs. (A): Representative images of caspase
3 and PARP Western blots. Quantiﬁcation of full length [35 kDa, (B)]
and cleaved [19 kDa (C), 17 kDa (D)] caspase 3. Quantiﬁcation of full
length [110 kDa, (E)] and cleaved [89 kDa, (F)] PARP. (G): Quantiﬁca-
tion of senescence associated b-galactosidase (SABG) positive CDCs
with representative images (3100). Scale bars are equal to 200 mm.
Data is presented as mean and standard error of the mean. *, p val-
ue .05; **, p value .01. Abbreviations: DMSO, dimethyl sulfox-
ide; PARP, poly(ADP-ribose) polymerase; SABG, senescence
associated b-galactosidase.
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for senescence associated b-galactosidase (SABG), poor supporter
CDCs were found to have a signiﬁcantly higher number of positive
cells, suggesting these cells are senescent (Fig. 5G, p val-
ue5 .0086). To determine which senescent pathways were differ-
entially regulated in poor supporters, levels of three classical
senescence markers; p16, p21, and p53 were investigated. Surpris-
ingly, there were no differences in the three senescence markers
between good and poor supporter CDCs (Supporting Information
Fig. 3). p16, p21, and p53 were expressed ubiquitously in the
CDCs tested, irrespectively of their vascular supportive ability.
These data suggest that CDCs with poor supportive function are
senescent but classical senescence markers are not suitable for
detecting senescence in this cell type.
Vascular Supportive Function In Vitro Correlates With
Therapeutic Potential In Vivo
To test the hypothesis that the differences in supportive CDC func-
tion observed in vitro can represent their therapeutic potential, a
preliminary in vivo study was conducted. MI was induced by LAD
ligation in athymic nude rats (HIH-Foxn1 rnu) and good supporter
CDCs, poor supporter CDCs or a saline control were injected into
the rat myocardium. Cardiac functional parameters were assessed
at baseline, day 15 and day 30 to evaluate the functional recovery
(Fig. 6, Supporting Information Fig. 4). Systolic function estimated
by percentage of fractional area change (FAC) was signiﬁcantly
improved by infusion of good supporter CDCs compared to con-
trol at day 15 (Fig. 6A, p value5 .031). Fractional shortening (FS)
improved following injection of good supporter CDC at day 15
when compared to control (Fig. 6B, p value5 .017). Infusion of
good supporter CDCs improved systolic function measured by FAC
or FS when compared to poor supporters (Fig. 6A, 6B, FAC p val-
ue5 .48, FS p value5 .012). Poor supporter CDCs had no signiﬁ-
cant effect on FAC or FS compared to saline control (Fig. 6A, 6B,
FAC p value5 .745, FS p value5 .728). Changes in the anterior
wall of the left ventricle (LV) were measured as a percentage of
aortic wall thickness (AWT), at day 15 animals injected with good
supporter CDCs had a signiﬁcantly higher AWT than animals
injected with poor supporter CDCs (Fig. 6C, p value5 .017). How-
ever, the difference between the good supporters and saline treat-
ment groups was not signiﬁcant (Fig. 6C, p value5 .295).
Surprisingly, the AWT percentage in rats treated with CDCs from
the poor supporters seemed to be worse than in the saline
treated groups (Fig. 6C, p value5 .208). Finally, infusion of good
supporter CDCs signiﬁcantly improved EF at day 15 when com-
pared to the saline group or poor supporter CDC infusion (Fig. 6D,
vs. saline p value5 .012 vs. poor p value5 .011). No changes in
EF were detected after infusion with poor supporter CDCs when
compared to the saline control (Fig. 6D, day 15 p value5 .793).
Angiogenesis, measured by capillary vessel density in the LV
was signiﬁcantly improved by good supporter CDC infusion com-
pared to the saline control (Fig. 6E, p value5 .005). In contrast,
animals injected with poor supporter CDCs did not show a
Figure 6.
Figure 6. Effect of cardiosphere-derived cell (CDC) transplantation
on LV function, capillary density and infarct size. Adult athymic (HIH-
Foxn1rnu) rats had the left anterior descending LAD artery ligated.
Animals were split into three groups which received either CDCs
from good supporters, CDC from poor supporters or saline as a con-
trol. Echocardiography was used to measure heart function at base-
line and 15 days. (A): Percentage of fractional area change (FAC %).
(B): Percentage of fractional shortening (FS %) change. (C): Percent-
age of anterior wall thickening (AWT %). (D): Percentage change in
left ventricular ejection fraction (LVEF %). 30 days following trans-
plantation of CDCs or saline the hearts were excised, sectioned and
stained with anti-caveolin antibody or with Masson’s trichrome
stain. (E): Quantiﬁcation of capillary density (vessels/mm2) in the
hearts of animals infused with good supporters, poor supporters or
saline control as measured by caveolin immunostaining, with repre-
sentative images (3200, scale bars are equal to 50 mm). (F): Quanti-
ﬁcation of infarct size (% of LV wall) in the hearts of animals infused
with good supporters, poor supporters or saline control as meas-
ured by Masson’s trichrome stain, with representative images (scale
bars are equal to 2 mm). In (F), the ﬁbrotic tissue around the infarct
stains blue against the healthy myocardium in red. Data is presented
as mean and standard error of the mean. *, p value .05;
**, p value .01. Abbreviations: AWT, aortic wall thickness; FAC %,
percentage of fractional area change; FS %, percentage of fractional
shortening; LVEF, left ventricular ejection fraction.
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signiﬁcant change in vessel density compared to animals injected
with saline (Fig. 6E, p value5 .817). Animals treated with good or
poor supportive CDCs showed a reduction of the ﬁbrotic scar size
compared to control animals, but this trend was not signiﬁcant
(Fig. 6F, good p value5 .92, poor p value5 .064). These results
suggest that CDCs from both groups can partially reduce the
ﬁbrotic scar to the same extent, but only those with a robust
angiogenic potential increase vessel density and improve systolic
function in the ischemic heart.
DISCUSSION
The variable results obtained in cardiac regenerative cell therapy
trials call for a personalized approached to cell therapy and the
need to develop better potency assays. Therefore, it is crucial to
select the optimal cell type and the best responder patient popu-
lation who would beneﬁt most from such therapies. In this study,
CDCs were isolated and expanded from a cohort of patients
undergoing elective cardiac surgery reﬂective of the epidemiology
of cardiovascular disease [36]. To our knowledge, this is the ﬁrst
time that therapeutic potential due to differences in the CDC’s
vascular supportive ability have been reported in this patient
cohort. CDCs were grouped according to their ability to support
vascular tubule formation in vitro. Traditionally, the expression of
single cell surface markers that could deﬁne a therapeutic cell
population has been sought. Recently, the expression of CD90 has
been associated with the therapeutic potential of CDCs in humans
[37]. However, in the current study the supportive ability of CDCs
did not correlate with CD90 expression or indeed any other cell
surface marker tested. A multiple regression model used to link
CDCs’ vascular supportive ability with donor characteristics indi-
cated patients with advanced disease state (higher NYHA class,
aortic stenosis and diseased right coronary artery) and/or were
previous smokers were more likely to produce good supporter
CDCs, while hypertension appeared to be a signiﬁcant negative
predictor of CDCs vascular supportive function. This is in agree-
ment with recent studies suggesting that CDCs from adult and
pediatric patients with advanced heart failure outperformed CDCs
from healthy donor hearts or control heart disease when tested in
a rodent model of MI [7, 38]. In our study, hypertension is a signif-
icant negative independent predictor of CDCs’ vascular supportive
ability. A new report has suggested that offspring born to hyper-
tensive mothers have reduced vasculogenic potential at birth and
this correlates with loss of microvessel density over the ﬁrst three
months of life [39], which suggest a correlation between in vitro
and in vivo vascular development. Patients included in our study
were neither treated with the isolated CDCs nor were they
followed-up to monitor collateral vessel development. However, it
is plausible that patients who yield poor supporters CDCs may
have impaired collateral growth development.
Molecular analysis carried out in our study revealed only a
small number of differentially expressed genes and transcripts
between good and poor supporter CDCs. This was not surprising
as IHD is a common complex polygenic disease involving a combi-
nation of multiple genes, each contributing with small effects on
the phenotype, therefore it is important to identify functional bio-
markers that correlate with cell potency. In our study, poor sup-
porter CDCs were found to have reduced proliferative potential,
variability in CDCs growth patterns has previously been observed
but not necessarily associated to their therapeutic potential [8,
40]. In addition to reduced proliferative potential, poor supporter
CDCs were resistant to apoptotic stimuli and secreted higher
amounts of inﬂammatory cytokines, all of which are hallmarks of
cell senescence [34, 35]. The cell senescence associated secreted
proﬁle (SASP) is thought to be a stress response to signal for repair
and has been well characterized [34, 35, 41]. Interestingly, several
of these factors (inﬂammatory cytokines) were signiﬁcantly higher
in poor supporter CDCs at the mRNA (RNA-seq; CXCL1/GRO-a, IL-
1A, IL-1B, IL-8) and protein (cytokine array; GM-CSF, CCL20/MIP-
3a) level. Cell stress induces a complex response and it is unknown
why some cells undergo apoptosis and others induce or undergo
senescence. The outcome will most likely depend on the cell type,
DNA damage, genetic differences between donors and previous
environmental stresses and insults to which the cell has been
exposed [35, 42]. In addition to the increased SASP in poor sup-
porters, these cells expressed high levels of SABG. However, the
expression of classic senescent markers p16, p21, and p53 were
similar in good and poor supporter CDCs. This may be due to the
cell samples originating from patients of advanced age with IHD,
as both states can increase senescent markers [42, 43]. Recently, a
slight increase in SABG in CDCs from older patients has been
observed [30]. However, as in our study, the senescence markers
p16, p21, and p53 were expressed in the majority of CDCs tested
and did not correlate with SABG levels [30]. The presence of
senescence in CDCs may be a positive, as loss of these markers
can indicate immortalization and oncogenesis [35, 44]. Collec-
tively, these ﬁndings are particularly important for cell therapy as
previous studies in the ﬁeld have established negative p16 expres-
sion as a measure of cell ﬁtness [45]. Our study shows that these
markers are not sufﬁcient for detecting senescent CDCs and that
the ability to support tubule formation provides a better insight
into functional and therapeutic ability.
Results obtained in vitro using such functional assays have
been conﬁrmed in vivo in a preclinical model of MI.We have dem-
onstrated that transplantation of good supporter CDCs diminishes
ventricular remodeling compared to poor supporters or saline,
they signiﬁcantly improved systolic function in the rat model of
MI. Vascular supportive ability of CDCs tested in vitro was a predic-
tive measure of improved capillary density in vivo. Animals trans-
planted with CDCs showed a reduction of infarct size irrespective
of supportive potential, although this was not signiﬁcant. Taken
together these results suggest that only CDCs with robust pro-
angiogenic ability improved LV remodeling, systolic function and
capillary density. Cell senescence has previously been shown to
prevent MSC cell therapy rescue in an LPS-induced lethal endotox-
emia study [41] and reduced the therapeutic effect of CPC when
infused into a mouse model of MI [46].
CONCLUSION
In this study, CDCs classed as poor supporters had a reduced capa-
bility to support HUVEC tubule formation, an increased inﬂamma-
tory proﬁle, decreased proliferation, were resistant to apoptotic
insult and had a higher proportion of senescent cells. By contrast,
good supporter CDCs had a robust vascular supportive ability and
high proliferative potential. The tubule assay highlighted the dif-
ference between good and poor supporter CDCs from patients
with IHD and was predictive of in vivo outcomes; it could there-
fore be used as a potency assay for cell therapy. Assessing cell
potency is crucial to the success of cell therapies and while
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patients who could provide potent therapeutic cells could be ame-
nable to autologous transplantation, those providing cells with
impaired therapeutic potential could beneﬁt from rejuvenation
treatments [38, 46–48] or allogeneic cell transplantation [12, 14,
17, 18, 49, 50], enabling a personalized approach to cell therapy
and improving outcomes in clinical trials.
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